share_log

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

Benzinga ·  Sep 13, 2023 06:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment